Parabolas of medication use and discontinuation after myocardial infarction—are we closing the treatment gap?

Authors

  • Marie Hudson MD, MPH,

    Corresponding author
    1. Division of Clinical Epidemiology, the Research Institute of the McGill University Health Center, 687 Pine Avenue west, Building V, Montreal, Québec, Canada
    • Division of Clinical Epidemiology, The Research Institute of the McGill University Health Centre, 687 Pine Avenue west, Building V, Montreal, Québec Canada H3A 1A1.
    Search for more papers by this author
  • Hugues Richard,

    1. Division of Clinical Epidemiology, the Research Institute of the McGill University Health Center, 687 Pine Avenue west, Building V, Montreal, Québec, Canada
    Search for more papers by this author
  • Louise Pilote

    1. Division of Clinical Epidemiology, the Research Institute of the McGill University Health Center, 687 Pine Avenue west, Building V, Montreal, Québec, Canada
    Search for more papers by this author

  • No conflict of interest was declared.

Abstract

Purpose

Little is known on the use of evidence-based medications in patients with acute myocardial infarction (AMI) across all ages. We undertook this study to describe the patterns of prescription and discontinuation of anti-platelet agents, beta-blockers, angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs) and statins in all patients post-AMI.

Methods

Using population-based administrative databases, patients with an AMI between 1999 and 2004 (21 494 men and 13 241 women) were identified. Rates of prescriptions after discharge and time to discontinuation of the study drugs were computed for various age groups.

Results

The proportion of patients prescribed a study drug increased throughout the study period. In 2003–2004, 90% of patients were prescribed an anti-platelet agent, 77% a beta-blocker, 72% a statin and 70% an ACE inhibitor and/or an ARB within 30 days of discharge from their AMI. However, the rates of discontinuation increased significantly during follow-up and, in men, reached 27% by 2 years and 42% by 5 years for beta-blockers. The rates of discontinuation of all four study drugs had a parabolic shape with the youngest and oldest patients having the highest rates.

Conclusions

The use of evidence-based drugs for patients after AMI is increasing. However, efforts aimed at closing the treatment gap may be mitigated by high rates of discontinuation, especially in patients at the extremes of the age spectrum. Copyright © 2007 John Wiley & Sons, Ltd.

Ancillary